Recent update of PD-L1 inhibitor therapy and companion diagnostics

Bicheng Jiang

doi:10.1117/12.2669047

24 March 2023 Recent update of PD-L1 inhibitor therapy and companion diagnostics

Bicheng Jiang

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126115X (2023) https://doi.org/10.1117/12.2669047
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

PD1/PD-L1 is a suppressive pathway of immune response which can be exploited by cancers and cause immune evasion. PD-L1 inhibitors are developed to block PD1/PD-L1 interaction and maintain durable anti-tumor immune responses to improve patients’ conditions. The therapeutic effects and toxicity of PD-L1 inhibitors have been researched in multiple clinical studies showing favorable results in particular populations. Atezolizumab, avelumab, and durvalumab have been granted approval by FDA, and more novel drugs are undergoing clinical trials. Biomarkers including PD-L1, TMB, TIL, and companion diagnostics are being researched for the prediction and identification of eligible patients. This paper discusses the recent development and notable information of PD-L1 inhibitors including the FDA-approved therapies, developing therapies, biomarkers, and companion diagnostics.

Citation Download Citation

Bicheng Jiang "Recent update of PD-L1 inhibitor therapy and companion diagnostics", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126115X (24 March 2023); https://doi.org/10.1117/12.2669047

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available